Results 241 to 250 of about 111,871 (303)

The Flavivirus NS3 Protein: Its Multifaceted Roles and Therapeutic Potential

Journal of Medical Virology, Volume 98, Issue 4, April 2026.
Abstract Mosquito‐borne flaviviruses are important human pathogenic viruses and can cause an array of symptoms ranging from asymptomatic to mild illness but can progress to severe disease conditions. Prominent members of the family Flaviviridae include Dengue virus, Zika virus, and West Nile virus, whose spread has increased globally due to the ...
Haejeong Lee, Hee Cho, Michaela U. Gack
wiley   +1 more source

PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis. [PDF]

Eur Urol Open Sci
Li Y, Li Z, Lu H, Shi P, Liu Y, Liu L, Chen K.   +6 more
europepmc   +1 more source

A Combination of Xanthohumol and Ursolic Acid in the Diet Leads to Synergistic Inhibition of Prostate Cancer Progression

Molecular Carcinogenesis, Volume 65, Issue 4, Page 508-522, April 2026.
ABSTRACT Prostate cancer (PCa) is the second most common cancer and second leading cause of cancer death for American men. Chemoprevention by using phytochemicals offers a promising approach to improve outcomes due to their ability to act on cancer cell metabolism and growth while maintaining low toxicity profiles.
Rachel Clark, Achinto Saha, G. Lavender Hackman, Chelsea A. Friedman, Ruggiero Gorgoglione, Stefano Tiziani, John DiGiovanni   +6 more
wiley   +1 more source

PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7. [PDF]

NAR Cancer
Colón-Ríos DA, Dow J, Krysztofiak A, Liu Y, Rogers FA, Glazer PM.   +5 more
europepmc   +1 more source

The Homeobox Genes: Classification, Regulation, Biological Functions, and Diseases

MedComm, Volume 7, Issue 4, April 2026.
Overview of the homeobox gene superfamily and its pathophysiological roles. The homeobox superfamily comprises several major classes, including ANTP, PRD, TALE, LIM, POU, and others. Among these, the HOX clusters (A–D) play critical roles in embryonic development specifically in conferring cellular identity, regulating morphogenesis, and guiding axial ...
Maedeh Dadzadi, Shahin Ramazi, Mona Darvazi, Sepideh Yoosefi, Melika Abbasi, Shirin Farsad   +5 more
wiley   +1 more source

Hypoxia-related signatures predicts survival, immunosuppression and PARP inhibitor resistance in HCC. [PDF]

Discov Oncol
Su M, Duan H, Gu Y, Zhao J.
europepmc   +1 more source

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang, Yiqun Du, Yanchun Meng, Yizi Jin, Mingxi Lin, Xuchen Shao, Xiaojun Liu, Yuxin Mu, Yun Liu, Zhen Hu   +9 more
wiley   +1 more source

PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis.

JAMA Netw Open
Petousis S, Kahramanoglu I, Appenzeller-Herzog C, Angeles MA, Margioula-Siarkou C, Kacperczyk-Bartnik J, Bilir E, Chatzakis C, Caruso G, Bizzarri N, Dinas K, Bowtell DDL, Garsed DW, Ray-Coquard I, Ledermann JA, Friedlander M, Sotiriadis A, Heinzelmann-Schwarz V, Zwimpfer TA.   +18 more
europepmc   +1 more source

Identification and validation of the PARP inhibitor-related gene KANK3 for predicting prognosis and immunotherapeutic response in prostate cancer. [PDF]

J Cancer
Zhao Y, Wang Q, Qin X, Jiang W, Li H, Xu M, Li X, Ye H, Zhou J, Chen X, Wu G.   +10 more
europepmc   +1 more source

Sulforaphane Synergizes With PD‐1 Blockade Through Activating CD8+ T Cells in Non–Small Cell Lung Cancer: Preclinical and Clinical Investigations

MedComm, Volume 7, Issue 4, April 2026.
SFN sensitizes PD‐1 blockade therapy in preclinical and clinical investigations, with no side effects. SFN elevates the antitumor response in peripheral and tumor microenvironment. ABSTRACT Anti‐PD‐1/PD‐L1 therapy has achieved promising success across several tumor types; however, its efficacy is still far from satisfactory in non–small cell lung ...
Jieyao Li, Jinyan Liu, Zheng Wang, Ming Zhao, Mingming You, Ziyi Fu, Caijuan Guo, Tengyue Zhang, Shasha Liu, Dongli Yue, Shuangning Yang, Yixin Li, Qun Gao, Yanfen Liu, Jianmin Huang, Liping Wang, Yi Zhang   +16 more
wiley   +1 more source